Literature DB >> 7532479

Combination chemotherapy with mitomycin C and cisplatin for advanced gastric cancer with multiple liver metastases.

Y Saikawa1, T Kubota, T Furukawa, K Kumai, K Yoshino, K Ishibiki, M Kitajima.   

Abstract

A patient with advanced gastric cancer with multiple liver metastases was treated by reduction surgery at the primary site as well as by the intraarterial administration of mitomycin C (MMC) and cisplatin (CDDP) through a reservoir catheter inserted into the proper hepatic artery. After a palliative subtotal gastrectomy, MMC 8 mg/m2 was administered intraarterially (i.a.) followed by the administration of CDDP 80 or 40 mg/m2 i.a. with an interval of less than 1 week. After the completion of five courses of this regimen, a complete reduction of the hepatic tumors was achieved, while the level of serum carcinoembryonic antigen decreased to the normal range. The patient is currently alive with signs of disease recurrence at 17 months after initial diagnosis, while additional therapy with MMC + CDDP was continuously undergone until 17 months' after initial diagnosis with various interval. Although thrombocytopenia occurred during the treatment, it resolved within a few weeks after completing the combination chemotherapy without any specific treatment. The present case showed a better prognosis than we had expected, which suggested that combination chemotherapy with MMC and CDDP might thus be clinically useful because of its excellent antitumor activity and low toxicity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7532479     DOI: 10.1007/bf01636313

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  11 in total

Review 1.  Mixed (composite) glandular-endocrine cell carcinoma of the stomach. Report of a case and review of literature.

Authors:  G C Yang; H Rotterdam
Journal:  Am J Surg Pathol       Date:  1991-06       Impact factor: 6.394

2.  Combination chemotherapy for advanced adenocarcinoma of the cervix.

Authors:  R Bates; G Deppe; J M Malone; H Budev; C W Christensen; V K Malviya
Journal:  Cancer       Date:  1991-08-15       Impact factor: 6.860

3.  Clinical usefulness of chemosensitivity testing using the MTT assay.

Authors:  T Furukawa; T Kubota; A Suto; T Takahara; H Yamaguchi; T Takeuchi; S Kase; S Kodaira; K Ishibiki; M Kitajima
Journal:  J Surg Oncol       Date:  1991-11       Impact factor: 3.454

4.  Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study.

Authors:  D S Alberts; R Kronmal; L H Baker; D L Stock-Novack; E A Surwit; J G Boutselis; E V Hannigan
Journal:  J Clin Oncol       Date:  1987-11       Impact factor: 44.544

5.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Authors:  M M Oken; R H Creech; D C Tormey; J Horton; T E Davis; E T McFadden; P P Carbone
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

6.  [Combined effect of CDDP with various types of antitumor drugs against P 388 leukemia].

Authors:  T Uchida; K Nishikawa; C Shibasaki; K Okamoto; M Arakawa; H Ekimoto; K Takahashi
Journal:  Gan To Kagaku Ryoho       Date:  1989-06

7.  Experimental and clinical activity of mitomycin C and cis-diamminedichloroplatinum in malignant mesothelioma.

Authors:  A P Chahinian; L Norton; J F Holland; L Szrajer; R D Hart
Journal:  Cancer Res       Date:  1984-04       Impact factor: 12.701

8.  Synergism of cisplatin and mitomycin C in sensitive and resistant cell subpopulations of a tumor model.

Authors:  R E Durand
Journal:  Int J Cancer       Date:  1989-11-15       Impact factor: 7.396

9.  Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity.

Authors:  A B Campbell; S M Kalman; C Jacobs
Journal:  Cancer Treat Rep       Date:  1983-02

10.  Synergistic antitumor activity of mitomycin C and cisplatin against gastric cancer cells in vitro.

Authors:  Y Saikawa; T Kubota; T H Kuo; S Kase; T Furukawa; H Tanino; K Ishibiki; M Kitajima
Journal:  J Surg Oncol       Date:  1993-10       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.